ZA988961B - Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds. - Google Patents

Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.

Info

Publication number
ZA988961B
ZA988961B ZA9808961A ZA988961A ZA988961B ZA 988961 B ZA988961 B ZA 988961B ZA 9808961 A ZA9808961 A ZA 9808961A ZA 988961 A ZA988961 A ZA 988961A ZA 988961 B ZA988961 B ZA 988961B
Authority
ZA
South Africa
Prior art keywords
azaquinoxaline
methods
protein kinase
based compounds
threonine protein
Prior art date
Application number
ZA9808961A
Other languages
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Gunther
Harald App
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA988961B publication Critical patent/ZA988961B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9808961A 1997-10-06 1998-10-01 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds. ZA988961B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06

Publications (1)

Publication Number Publication Date
ZA988961B true ZA988961B (en) 1999-10-04

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9808961A ZA988961B (en) 1997-10-06 1998-10-01 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.

Country Status (30)

Country Link
US (2) US6180631B1 (cg-RX-API-DMAC7.html)
EP (1) EP1028729B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001518496A (cg-RX-API-DMAC7.html)
KR (1) KR100633270B1 (cg-RX-API-DMAC7.html)
CN (1) CN1169527C (cg-RX-API-DMAC7.html)
AR (1) AR013542A1 (cg-RX-API-DMAC7.html)
AT (1) ATE336250T1 (cg-RX-API-DMAC7.html)
AU (1) AU757585B2 (cg-RX-API-DMAC7.html)
BG (1) BG64969B1 (cg-RX-API-DMAC7.html)
BR (1) BR9814814A (cg-RX-API-DMAC7.html)
CA (1) CA2306257C (cg-RX-API-DMAC7.html)
CY (1) CY1106223T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298775B6 (cg-RX-API-DMAC7.html)
DE (1) DE69835612T2 (cg-RX-API-DMAC7.html)
DK (1) DK1028729T3 (cg-RX-API-DMAC7.html)
ES (1) ES2268791T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0100302A3 (cg-RX-API-DMAC7.html)
IL (2) IL135103A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03011007A (cg-RX-API-DMAC7.html)
NO (1) NO316598B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ503431A (cg-RX-API-DMAC7.html)
PL (1) PL192039B1 (cg-RX-API-DMAC7.html)
PT (1) PT1028729E (cg-RX-API-DMAC7.html)
RU (1) RU2223753C2 (cg-RX-API-DMAC7.html)
SK (1) SK4722000A3 (cg-RX-API-DMAC7.html)
TR (2) TR200000906T2 (cg-RX-API-DMAC7.html)
TW (1) TWI245765B (cg-RX-API-DMAC7.html)
UA (1) UA71555C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999017759A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA988961B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
PT1636228E (pt) * 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
ATE454152T1 (de) * 2003-06-13 2010-01-15 Novartis Pharma Gmbh 2-aminopyrimidin-derivate als raf-kinase-hemmer
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014109414A1 (ja) * 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
US6180631B1 (en) 2001-01-30
WO1999017759A2 (en) 1999-04-15
KR20010030934A (ko) 2001-04-16
CZ20001129A3 (cs) 2000-10-11
IL135103A (en) 2007-06-17
CN1169527C (zh) 2004-10-06
HK1031836A1 (en) 2001-06-29
ES2268791T3 (es) 2007-03-16
IL135103A0 (en) 2001-05-20
NO20001748L (no) 2000-04-05
KR100633270B1 (ko) 2006-10-16
PL339860A1 (en) 2001-01-15
BR9814814A (pt) 2000-10-03
TR200000906T2 (tr) 2000-11-21
JP2001518496A (ja) 2001-10-16
UA71555C2 (en) 2004-12-15
RU2223753C2 (ru) 2004-02-20
AR013542A1 (es) 2000-12-27
NZ503431A (en) 2002-07-26
TR200100385T2 (tr) 2002-06-21
DE69835612T2 (de) 2007-08-16
EP1028729A2 (en) 2000-08-23
WO1999017759A3 (en) 2000-01-06
BG104392A (en) 2000-12-29
PL192039B1 (pl) 2006-08-31
SK4722000A3 (en) 2002-06-04
CN1274284A (zh) 2000-11-22
HUP0100302A3 (en) 2006-03-28
CA2306257A1 (en) 1999-04-15
US6727252B1 (en) 2004-04-27
TWI245765B (en) 2005-12-21
DE69835612D1 (de) 2006-09-28
HUP0100302A2 (hu) 2001-06-28
NO316598B1 (no) 2004-03-01
CA2306257C (en) 2007-09-25
BG64969B1 (bg) 2006-11-30
ATE336250T1 (de) 2006-09-15
CZ298775B6 (cs) 2008-01-23
EP1028729B1 (en) 2006-08-16
PT1028729E (pt) 2006-12-29
NO20001748D0 (no) 2000-04-05
AU757585B2 (en) 2003-02-27
MXPA03011007A (es) 2004-02-27
AU9514198A (en) 1999-04-27
DK1028729T3 (da) 2006-12-11
CY1106223T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
ZA988961B (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
ZA9810219B (en) Benzothiazole protein tyrosine kinase inhibitors.
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
IL141866A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ZA9810332B (en) Aminothiazone inhibitors of cyclin dependent kinases.
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU8547198A (en) Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxido squalene-cyclase
HU9600050D0 (en) Oligonucleotide modulation of protein kinase c
NO20003154D0 (no) Stikkplugg
AU6882598A (en) Protein kinase inhibitor
GB9817658D0 (en) Stabilizer mixture based on polyalkyl-l-oxa-diazaspirodecane compounds
HUP0103079A3 (en) Modulating multiple lineage kinase proteins
GB9926537D0 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
AU6049399A (en) Serine/threonine protein kinases
AU2538899A (en) Protein kinase c
EP1028947B8 (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
AU8778698A (en) Serine/threonine kinase, and uses related thereto
AU6421498A (en) Serine/threonine protein kinase
AU6546098A (en) Serine/threonine protein kinase